Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2000

01-12-2000 | Paper Report

HOXA5 regulation of p53 in breast tumours

Author: Chris Jones

Published in: Breast Cancer Research | Issue 1/2000

Login to get access

Excerpt

Mutational inactivation of p53 occurs in only around 20% of human breast cancers, suggesting other mechanisms for loss of p53 function in these tumours. Although much work has been performed on the control of p53 degradation, information is lacking regarding factors which regulate p53 synthesis.Class I homeobox (HOX) genes are a family of regulatory genes encoding transcription factors that primarily play a crucial role during development. Several indications suggest their involvement in the control of cell growth and, when dysregulated, oncogenesis. …
Literature
1.
Raman V, Martensen SA, Relsman D, Evron E, Odenwald WF, Jaffee E, Marks J, Sukumar S: Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature. 2000, 408: 974-978.
Metadata
Title
HOXA5 regulation of p53 in breast tumours
Author
Chris Jones
Publication date
01-12-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-2000-66711

Other articles of this Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue

Paper Report

Enhanced activity of anti-Lewisyhumanised 3S193 when combined with Taxol

Review

Breast imaging technology Application of magnetic resonance imaging to early detection of breast cancer

Paper Report

Tamoxifen, angiogenesis, oestrogens and animal models

Paper Report

Phase III trial of chemotherapy ? HerceptinR in metastatic breast cancer

Research article

Comparison of written reports of mammography, sonography and magnetic resonance mammography for preoperative evaluation of breast lesions, with special emphasis on magnetic resonance mammography

Paper Report

Her-2/neu and topoisomerase IIaexpression in primary and metastatic breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits